Nevro Files Lawsuit for Patent Infringement Against Boston Scientific in the U.S.

REDWOOD CITY, Calif., Nov. 28, 2016 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has filed a lawsuit for patent infringement against units of Boston Scientific (NYSE:BSX).  The lawsuit, filed in the United States District Court for the Northern District of California, asserts that Boston Scientific is infringing Nevro's patents covering inventions relating to Nevro's groundbreaking Senza® system and HF10™ therapy.  The lawsuit seeks preliminary and permanent injunctive relief against further infringement as well as damages and attorney's fees.  One of the asserted patents, U.S. patent no. 8,359,102, was the subject of two petitions for inter partes review (IPR) filed by Boston Scientific with the Patent Trial and Appeals Board (PTAB) of the U.S. Patent and Trademark Office.  On November 30, 2015, the PTAB declined to institute IPRs after finding that Boston Scientific failed to establish a reasonable likelihood of showing that even one of the challenged claims of the '102 patent was invalid.

"Nevro was founded in 2006 to develop meaningful advances in the treatment of chronic pain to improve patients' lives," said Rami Elghandour, President and CEO of Nevro.  "Intellectual property is the basis for innovation in health sciences given the long development timelines, investment, and risk required to bring meaningful advances to market.  We are committed to ensuring continued innovation in health sciences by protecting our intellectual property."

Documents relating to the lawsuit can be found via registration at the court's website, www.cand.uscourts.gov.  The case no. is 3:16-cv-06830.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Investor Relations Contact:

Nevro Investor Relations

Katherine Bock

(650) 433-3247

[email protected]

SOURCE Nevro Corp.

Related Links

http://www.nevro.com